S&P Futures
5,886.00 -20.00 (-0.34%) Dow Futures
43,422.00 -96.00 (-0.22%) Nasdaq Futures
20,358.50 -125.00 (-0.61%) Russell 2000 Futures
2,282.80 -8.40 (-0.37%) Crude Oil
70.77 +1.55 (+2.24%) Gold
2,750.30 +20.30 (+0.74%)
Oxford BioDynamics Plc (OBD.L)
| Previous Close | 1.1150 |
| Open | 1.1400 |
| Bid | 1.1300 x 0 |
| Ask | 1.1950 x 0 |
| Day's Range | 1.0800 - 1.2500 |
| 52 Week Range | 1.0000 - 38.8000 |
| Volume | |
| Avg. Volume | 2,868,852 |
| Market Cap | 3.524M |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0600 |
| Earnings Date | Jan 15, 2025 - Jan 20, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireOxford Biodynamics to present on its line of EpiSwitch® products for companion diagnostics in cancer immunotherapy at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics in Boston, MA.
OXFORD, England, July 25, 2024--Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on the EpiSwitch® 3D genomics platform [1], announces its key-note presentation at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics, taking place on 3-6 September 2024 in Boston, MA, USA.
Business WireOxford BioDynamics part of consortium shortlisted for Strategic Government Initiative to Improve Cancer Immunotherapy
OXFORD, England, June 25, 2024--Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on OBD’s EpiSwitch® 3D genomics platform,[4] announces that it has formed a strategic consortium which has been shortlisted for the UK Government’s Checkpoint Inhibitor Response Research Platform (CIRRP) award call for biomarker development around immunotherapies of cancer. If successful, the consortium’s
